Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 4361-4370 Newer>

The Motley Fool November 20, 2007 Brian Orelli	Explaining Onyx Pharmaceuticals' Sell-Off The FDA approved Nexavar as a treatment for liver cancer, but the good news causes a sell-off of the stock.
The Motley Fool November 19, 2007 Tom Taulli	Virtual Radiologic's Rad IPO The company, which has built a technology platform to help deal with the shortage of radiologists, attracts a lot of attention to its IPO.
The Motley Fool November 16, 2007 Brian Orelli	Weighing In on Amylin's Drug Combination Phase 2 results are good for Amylin Pharmaceuticals trial of a new weight-loss treatment, but it's the subsequent phase 3 trial that actually counts.
The Motley Fool November 16, 2007 Brian Lawler	Waiting on a Friend for Dendreon Dendreon looks for a marketing partner for a prostate cancer drug that's in clinical trials. Investors, take note.
The Motley Fool November 16, 2007 Brian Lawler	Trimeris Gets a Cleanup Hitter Tiny drug developer Trimeris announces that it has finally found a permanent CEO to help get itself in order following the resignation of its former leader a year ago.
The Motley Fool November 16, 2007 Brian Lawler	Scrutinizing FDA Drug Approvals Comparing the FDA's approval rate of new drugs by calendar year illustrates that the pace of approvals certainly has slowed since the 2004 recall of Merck's anti-inflammatory compound Vioxx.
The Motley Fool November 16, 2007 Billy Fisher	Megagrowth at Meridian Bioscience The biotech, a consistent performer for five years now, produces another quarter of record revenue and earnings. Investors, take note.
The Motley Fool November 15, 2007 Charly Travers	John Edwards, Frozen Caveman Lawyer Presidential hopeful John Edwards' health-care plans could destroy drug research and development in this country by removing the patent protection on breakthrough drugs.
The Motley Fool November 15, 2007 Brian Orelli	John Edwards' Not-So-Bad Plan John Edwards' plan to take away drug patents in exchange for a monetary price just may work, if the price is high enough.
The Motley Fool November 15, 2007 Brian Orelli	Slowing the Cash Burn Bloody Nose Nastech plans to cut costs following Proctor& Gamble's drop of their osteoporosis drug. Investors, take note.
<Older 4361-4370 Newer> Return to current articles.